Sub menu

 

 

TEICOPLANIN DEMOGEN (Demogen Australia Pty Ltd trading as DEMOGEN Pharmaceuticals)

Product name
TEICOPLANIN DEMOGEN
Sponsor
Demogen Australia Pty Ltd trading as DEMOGEN Pharmaceuticals
Date registered
Evaluation commenced
Decision date
Approval time
144 (255 working days)
Active ingredients
teicoplanin
Registration type
New generic medicine
Indication

TEICOPLANIN DEMOGEN is indicated for the treatment of the following serious infections due to staphylococci or streptococci, which cannot be treated satisfactorily with less toxic agents, including β-lactam antibiotics:

  • Bone: osteomyelitis
  • Joints: septic arthritis
  • Blood: non-cardiac bacteraemia, septicaemia